Your session is about to expire
← Back to Search
Tocilizumab for Craniopharyngioma
Study Summary
This trial is testing a new cancer treatment. Patients with new or recurrent/ progressed craniopharyngioma tumors will be given tocilizumab, a drug that may help shrink the tumor. The study will be conducted in two phases, and patients will be followed for up to 5 years.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2017 Phase 4 trial • 59 Patients • NCT02034474Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My kidney function, based on my age and gender, meets the required levels.My kidney function is normal.I have an irregular heartbeat.My ACP has come back or gotten worse after surgery and radiation.I do not have any ongoing or active infections.My cancer has spread to other parts of my body.My doctor plans to remove or test a part of my tumor for my treatment.My doctors think I have a brain tumor called craniopharyngioma based on my scans.My liver is working well.You need to have a good score on a test that shows how well you can perform certain tasks.My cancer has grown or changed after treatment, as confirmed by my doctor.My child is active and can do most activities without help.I am between 2 and 20 years old.I have previously been treated with tocilizumab or other IL6 inhibitors.My previously confirmed ACP has gotten worse or come back.My ACP came back or got worse after surgery without radiation.I have symptoms of heart failure.I am able to care for myself and perform daily activities.You have had a severe allergic reaction or anaphylaxis to tocilizumab in the past.My liver tests are within normal limits for my age.My bone marrow is working well.My organs are functioning well.I am over 16 and can care for myself but may not be able to do active work.I have a newly diagnosed ACP that can't be fully removed and is measurable.I cannot come back for follow-up visits or get tests to check treatment side effects.I have not had any live vaccines in the last 3 months.I do not have any serious illnesses that are not under control.I have unstable chest pain.
- Group 1: Tocilizumab Administration: Feasibility Phase
- Group 2: Tocilizumab Administration: Phase 0
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this trial extend to individuals past the age of eighty?
"To be eligible for this trial, participants must have an age ranging from 2 years to 21 years. There are 18 studies available to those younger than 18 and 67 studies allocated for individuals over 65."
Who is eligible to join the experiment?
"This clinical trial is seeking roughly 27 participants who have adamantinous craniopharyngioma, aged between 2 and 21 years old."
Are there any additional investigations involving Tocilizumab?
"Currently, Tocilizumab is being investigated in a total of 71 clinical trials, with 8 of them currently in Phase 3. While many studies are conducted out of Poznan and New york City, 1455 medical centres around the globe have registered to run research into this drug."
Could you summarize the major goals of this trial?
"This long-term study has one primary objective: to measure the presence of Tocilizumab and its metabolites. There are also three secondary objectives, which include determining cytokine signaling in tumor tissue or cyst fluid using ELISA, gauging overall response rate with radiography for newly diagnosed ACP cases given systemic tocilizumab therapy, and demonstrating immune cell infiltration in tumor tissues via immunohistochemistry and flow cytometry."
Are there any current opportunities for individuals to join this trial?
"Clinicaltrials.gov suggests that enrollment is still open for this medical investigation, which was first posted on June 27th 2019 and subsequently edited on May 16th 2022."
How many individuals are being given the opportunity to participate in this trial?
"Affirmative. According to clinicaltrials.gov, this trial became available on June 27th 2019 and is currently enrolling participants. To date, the study has identified 1 site for recruitment and needs to fill in 27 spots."
Share this study with friends
Copy Link
Messenger